Of these, the cognate receptors for glucagon(GCG), glucagon-like peptide-1 (GLP-1), and gastric inhibitory peptide(GIP), or GCGR, GLP-1R, GIPR, respectively, have garnered widespreadattention in the past decade as promising therapeutic targets by thepharmaceutical industry for both the treatment of type two diabetesas well as obesity. Indeed, numerous monoagoniststargeting the GLP-1R, including semaglutide, dulaglutide, and exenatide, are FDA-approved drugs that have shown remarkablesuccess in the treatment of type 2 diabetes mellitus. Here, GCG is linked to obesity disorder.